Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant

Episode Summary

Executive Summary: Russ Roberts and Vinay Prasad argue that many cancer drugs are overpriced relative to their modest or uncertain benefits, largely because Medicare, FDA approval rules, and conflicted experts create a broken quasi-market. They discuss weak endpoints, distorted trials, financial conflicts, and policy reforms aimed at restoring evidence, accountability, and value in cancer care.

Main Topics: Poor value of many cancer drugs (Priority: 5/5): Prasad argues that while a few breakthrough drugs exist, most approved cancer drugs provide only marginal survival gains at very high cost, producing poor cost-effectiveness. Broken pricing and reimbursement system (Priority: 5/5): The discussion centers on how Medicare must cover FDA-approved cancer drugs and often off-label uses, while lacking negotiating power, so prices reflect political and institutional loopholes more than true market discipline. Surrogate endpoints and weak evidence (Priority: 5/5): The speakers critique approval based on tumor shrinkage or progression-free survival rather than meaningful outcomes like overall survival or quality of life, noting that such endpoints can mislead clinicians and patients. Conflicts of interest in oncology (Priority: 5/5): Prasad describes how patient groups, key opinion leaders, journals, universities, and professional societies are often financially tied to industry, shaping the narrative and lowering evidentiary standards. Regulatory reform and trial redesign (Priority: 4/5): Prasad proposes changing who designs and controls registration trials, with regulators or third parties pre-registering trial methods to reduce sponsor manipulation and improve reliability. Patient trust and informed choice (Priority: 4/5): Roberts and Prasad discuss the erosion of trust when doctors and institutions have financial incentives, emphasizing the need for transparency, second opinions, and patient questions about expected benefit. International comparisons and public policy trade-offs (Priority: 4/5): They compare U.S. cancer-drug policy with the UK and other countries, debating cost-effectiveness, access, and the global influence of U.S. drug pricing on innovation.

Key Arguments: Most cancer drugs deliver only modest median survival benefit, so high prices generate very poor value for patients and society. Cancer medicine is not a true market because reimbursement is insulated from consumer choice; Medicare must pay for approved drugs and cannot negotiate price. Off-label coverage and conflicted expert panels expand payment for uses with weak or anecdotal evidence. Clinical trials are often designed by sponsors with strong incentives to favor positive results through comparator choice, patient selection, dosing, and endpoint choice. Surrogate endpoints like tumor shrinkage are imperfect proxies for what patients care about and can create the illusion of benefit. Many influential figures in oncology are paid directly or indirectly by industry, which can soften criticism and shape guidelines, publications, and policy. The solution is not to blame individuals but to change incentives and institutional design so that good behavior is rewarded and conflicts are reduced. Some uncertainty at approval may be acceptable if it is later resolved through strong post-market confirmation and removal of ineffective drugs, but that rarely happens now. Patients should ask better questions about benefits, alternatives, and what happens if they do nothing, especially when recommendations come from conflicted sources. The U.S. system effectively subsidizes global pharmaceutical innovation by allowing higher drug prices than other rich countries. The status quo pleases neither advocates of more regulation nor free-market advocates because it is a distorted hybrid that encourages waste and overuse.

Data Points: Median overall survival gain for 71 solid-tumor drugs: 2.1 months - Cited from a JAMA Otolaryngology study to illustrate typical marginal benefit of newly approved cancer drugs. Typical monthly drug price: $12,000-$16,000 per month - Prasad describes common prices for noncurative cancer drugs taken indefinitely. Regorafenib cost-effectiveness: $900,000 per QALY - Example used to show how poor value can become in colon cancer. UK cost-effectiveness ceiling mentioned: $60,000-$70,000 per QALY - Roberts describes approximate thresholds often used in the UK. Possible U.S. cost-effectiveness ceiling mentioned: $200,000-$250,000 per QALY - Roberts cites economists who argue this may be an upper bound for the U.S. Share of drugs with meaningful benefit (approximate): About one-third - Prasad says roughly one-third of recent oncology approvals improve survival, quality of life, or patient-reported outcomes. Share of drugs approved on progression/recurrence endpoints: About one-third - Prasad says another third are approved on surrogate endpoints rather than patient-important outcomes. Share of drugs approved without a control arm: About one-third - Prasad says the remaining third rely on single-arm response-rate studies. FDA reviewer revolving-door risk: 60% - Prasad states that about 60% of FDA reviewers go on to work for industry after leaving the agency. Financial payments to some experts: $100,000-$300,000 per year - Prasad describes consulting, speaking, and CME payments received by some oncology leaders. U.S. share of global pharmaceutical revenue: About half - Roberts notes that around 50% of worldwide pharmaceutical revenue comes from the U.S. market. Cancer Drug Fund example: Created about a decade earlier - Used in the UK as a politically driven exception to standard cost-effectiveness review.

Pivotal Quotes: "For the most part, cancer drugs cost too much and deliver too little." — Vinay Prasad: Opening thesis from Prasad’s book and central claim of the interview. "the market is a broken, convoluted system that exerts nearly no downward force on cancer drug prices." — Vinay Prasad: Prasad explains why cancer-drug pricing does not behave like a normal competitive market. "The magnetic pull of profit, regulatory capture, and hype have resulted in policies that lead us astray from the best interests of people with cancer." — Vinay Prasad: Roberts reads the book’s closing summary statement at the end of the conversation.

Implications: Listeners are urged to question high-priced cancer care, demand evidence tied to outcomes that matter, and recognize how incentives shape medicine. The episode suggests reforms in FDA review, Medicare payment, and conflict-of-interest rules could improve value and trust.